$AMGN Headlines FDA panel recommends approval
Post# of 72711
Posted On: 01/14/2015 10:25:19 AM
$AMGN Headlines
FDA panel recommends approval for first generic biotech drug 4:51 p.m. Jan. 7, 2015 - Wallace Witkowski
Novartis wins FDA staff Ok for Neupogen generic 12:46 p.m. Jan. 5, 2015 - Marta Falconi
Amgen and Kite Pharma in cancer immunotherapy pact 10:00 a.m. Jan. 5, 2015 - Tess Stynes
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Express Scripts is Biotech's Grinch 9:13 a.m. Today - Seeking Alpha
Ziopharm up big on CAR-T license deal 8:25 a.m. Today - Seeking Alpha
Illumina Partners Lockheed Martin for Genomics Solutions - Analyst Blog 6:45 p.m. Jan. 13, 2015 - Zacks.com
Perrigo/Ferrara Candy Ink Supply Deal for Gummy Products - Analyst Blog 6:30 p.m. Jan. 13, 2015 - Zacks.com
Express Scripts Eyes New Price War: Anti-PCSK9 Drugs 6:06 p.m. Jan. 13, 2015 - Investors Business Daily
Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst Blog 5:51 p.m. Jan. 13, 2015 - Zacks.com
Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - Analyst Blog 5:00 p.m. Jan. 13, 2015 - Zacks.com
Express Scripts CEO: Amgen, Regeneron, Cancer Drugs Next Targets for Drug Discounting 12:46 p.m. Jan. 13, 2015 - TheStreet.com
Amgen's Decline May Be Linked To Comments Of Express Script's CEO 12:18 p.m. Jan. 13, 2015 - benzinga.com
Short Interest in Biotechs Signals Optimism 7:58 a.m. Jan. 13, 2015 - 247WallSt.com
Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst Blog 7:20 p.m. Jan. 12, 2015 - Zacks.com
Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog 6:30 p.m. Jan. 12, 2015 - Zacks.com
Conatus Announced Results from Emricasan Studies - Analyst Blog 5:10 p.m. Jan. 12, 2015 - Zacks.com
AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst Blog 5:00 p.m. Jan. 12, 2015 - Zacks.com
Amgen collaborates with leading cancer center on BiTE technology 4:52 p.m. Jan. 12, 2015 - Seeking Alpha
Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog 4:00 p.m. Jan. 12, 2015 - Zacks.com
Regeneron Can Generate 25% Upside for Investors 1:44 p.m. Jan. 12, 2015 - Barrons.com
Hospira submits BLA for biosimilar to Amgen product 9:46 a.m. Jan. 12, 2015 - Seeking Alpha
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog 5:05 p.m. Jan. 9, 2015 - Zacks.com
Crude Awakening As Energy Squeezes Overall Q4 Profit 4:58 p.m. Jan. 9, 2015 - Investors Business Daily
NantWorks Announces Launch of an Immuno-Oncology Company, NantCell, and Licensing Agreement with Amgen for an Oncology Antibody 8:01 a.m. Today - BusinessWire - BZX
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco 5:00 a.m. Jan. 13, 2015 - BusinessWire - BZX
Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome 4:01 p.m. Jan. 12, 2015 - PR Newswire - PRF
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar 9:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine 8:00 a.m. Jan. 9, 2015 - PR Newswire - PRF
Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference 4:15 p.m. Jan. 8, 2015 - PR Newswire - PRF
Surface Oncology Announces $35 Million Series A Financing to Advance Next-Generation Cancer Immunotherapies 7:30 a.m. Jan. 8, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma 8:35 a.m. Dec. 31, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Dec. 17, 2014 - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
FDA panel recommends approval for first generic biotech drug 4:51 p.m. Jan. 7, 2015 - Wallace Witkowski
Novartis wins FDA staff Ok for Neupogen generic 12:46 p.m. Jan. 5, 2015 - Marta Falconi
Amgen and Kite Pharma in cancer immunotherapy pact 10:00 a.m. Jan. 5, 2015 - Tess Stynes
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Barbara Kollmeyer
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:57 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:06 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Amgen, under investor pressure, outlines strategy 10:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 9:07 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 8:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 8:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 8:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 8:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 8:51 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
4 more ‘Amazon’ stocks you may want to avoid 8:43 p.m. Oct. 27, 2014 - Philip van Doorn
Express Scripts is Biotech's Grinch 9:13 a.m. Today - Seeking Alpha
Ziopharm up big on CAR-T license deal 8:25 a.m. Today - Seeking Alpha
Illumina Partners Lockheed Martin for Genomics Solutions - Analyst Blog 6:45 p.m. Jan. 13, 2015 - Zacks.com
Perrigo/Ferrara Candy Ink Supply Deal for Gummy Products - Analyst Blog 6:30 p.m. Jan. 13, 2015 - Zacks.com
Express Scripts Eyes New Price War: Anti-PCSK9 Drugs 6:06 p.m. Jan. 13, 2015 - Investors Business Daily
Biogen to Acquire Convergence, Expand Pain Pipeline - Analyst Blog 5:51 p.m. Jan. 13, 2015 - Zacks.com
Aegerion Reveals Preliminary 2014 Results and 2015 Outlook - Analyst Blog 5:00 p.m. Jan. 13, 2015 - Zacks.com
Express Scripts CEO: Amgen, Regeneron, Cancer Drugs Next Targets for Drug Discounting 12:46 p.m. Jan. 13, 2015 - TheStreet.com
Amgen's Decline May Be Linked To Comments Of Express Script's CEO 12:18 p.m. Jan. 13, 2015 - benzinga.com
Short Interest in Biotechs Signals Optimism 7:58 a.m. Jan. 13, 2015 - 247WallSt.com
Regeneron/Sanofi Seek PCSK9 Drug Praluent Approval in EU - Analyst Blog 7:20 p.m. Jan. 12, 2015 - Zacks.com
Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog 6:30 p.m. Jan. 12, 2015 - Zacks.com
Conatus Announced Results from Emricasan Studies - Analyst Blog 5:10 p.m. Jan. 12, 2015 - Zacks.com
AMAG Provides 2014 Preliminary Results & 2015 Guidance - Analyst Blog 5:00 p.m. Jan. 12, 2015 - Zacks.com
Amgen collaborates with leading cancer center on BiTE technology 4:52 p.m. Jan. 12, 2015 - Seeking Alpha
Vertex Pharmaceuticals' Kalydeco Remains in Focus in 2015 - Analyst Blog 4:00 p.m. Jan. 12, 2015 - Zacks.com
Regeneron Can Generate 25% Upside for Investors 1:44 p.m. Jan. 12, 2015 - Barrons.com
Hospira submits BLA for biosimilar to Amgen product 9:46 a.m. Jan. 12, 2015 - Seeking Alpha
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog 5:05 p.m. Jan. 9, 2015 - Zacks.com
Crude Awakening As Energy Squeezes Overall Q4 Profit 4:58 p.m. Jan. 9, 2015 - Investors Business Daily
NantWorks Announces Launch of an Immuno-Oncology Company, NantCell, and Licensing Agreement with Amgen for an Oncology Antibody 8:01 a.m. Today - BusinessWire - BZX
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco 5:00 a.m. Jan. 13, 2015 - BusinessWire - BZX
Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome 4:01 p.m. Jan. 12, 2015 - PR Newswire - PRF
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar 9:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine 8:00 a.m. Jan. 9, 2015 - PR Newswire - PRF
Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference 4:15 p.m. Jan. 8, 2015 - PR Newswire - PRF
Surface Oncology Announces $35 Million Series A Financing to Advance Next-Generation Cancer Immunotherapies 7:30 a.m. Jan. 8, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma 8:35 a.m. Dec. 31, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 10:23 a.m. Dec. 17, 2014 - PR Newswire - PRF
TetraLogic Provides Update on Ovarian Cancer Study 7:01 a.m. Dec. 16, 2014 - GlobeNewswire
Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4:01 p.m. Dec. 11, 2014 - PR Newswire - PRF
Frequentz Broadens Expertise in Traceability Space with Addition of Lew Kontnik as Strategic Advisor 4:05 p.m. Dec. 10, 2014 - PR Newswire - PRF
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 9:00 p.m. Dec. 8, 2014 - PR Newswire - PRF
New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma 4:20 p.m. Dec. 8, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼